Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Comey to be arraigned in federal court after...
Comey pleads not guilty in court after indictment...
Houthi rebels test US ceasefire with deadly strike...
Kushner joins Witkoff for Gaza ceasefire talks as...
Cuomo rips Mamdani’s freebie ‘fantasy,’ says AOC proved...
White House escalates shutdown consequences as Democrats show...
Moderate Dem undercuts Jeffries on ObamaCare compromise as...
MIKE DAVIS: The Supreme Court betrayed again —...
Senate Democrats defy White House warnings, again block...
Greta Thunberg slammed for using image of starved...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Soaring Medicare prescription drug prices targeted in Trump’s new executive order

by admin April 16, 2025
April 16, 2025
Soaring Medicare prescription drug prices targeted in Trump’s new executive order

President Donald Trump is seeking to combat soaring prescription drug prices in a new executive order he signed Tuesday. 

The order instructs Robert F. Kennedy Jr.’s Department of Health and Human Services (DHS) to standardize Medicare payments for prescription drugs — including those used for cancer patients — no matter where a patient receives treatment. This could lower prices for patients by as much as 60%, according to a White House fact sheet.

Likewise, the order also calls to match the Medicare payment for certain prescription drugs to the price that hospitals pay for those drugs — up to 35% lower than what the government pays to acquire those medications, the White House said. 

The order also takes steps to lower insulin prices. Specifically, the order calls for lowering insulin prices for low-income patients or those that are uninsured to as little as three cents, and injectable epinephrine to treat allergic reactions to as low as $15, coupled with a ‘small administrative fee,’ according to a White House fact sheet. 

Additionally, the order attempts to drive down states’ drug prices by ‘facilitating importation programs that could save states millions in prescription drug prices,’ as well as bolstering programs that assist states secure deals on sickle-cell medications in Medicaid, the fact sheet said. 

The order also requires DHS to seek comment on the Medicare Drug Price Negotiation Program, which the Biden administration authorized under the Inflation Reduction Act and allows Medicare to directly engage in hashing out prescription prices with drug companies. 

‘The guidance shall improve the transparency of the Medicare Drug Price Negotiation Program, prioritize the selection of prescription drugs with high costs to the Medicare program, and minimize any negative impacts of the maximum fair price on pharmaceutical innovation within the United States,’ the order said. 

Drug prices have significantly ramped up in recent years. Between January 2022 and January 2023, prescription drug prices rose more than 15% and reached an average of $590 per drug product, according to the Department of Health and Human Services. Of the 4,200 prescription drugs included on that list, 46% of the price increases exceeded the rate of inflation. 

Previous efforts under the first Trump administration to curb prescription drug prices included installing a cap on Medicaid prescription drug plans for insulin at $35. 

Meanwhile, Trump’s 145% tariffs on Chinese imports to the U.S. could mean that healthcare costs are particularly susceptible to price increases. Market research group Black Book Research found that 84% of experts predict that prices for medical treatments and drugs will rise due to the tariffs, according to a survey released in February. 

Additionally, Trump signaled Monday that tariffs on the pharmaceutical were headed down the pipeline. 

‘We don’t make our own drugs anymore,’ Trump told reporters Monday. ‘The drug companies are in Ireland, and they’re in lots of other places, China.’

Trump signed the executive order Tuesday, along with others that seek to prevent illegal immigrants from accessing Social Security benefits, and another one calling to investigate the impact of imported processed mineral on national security. 

Tuesday’s executive order comes days after the Department of Health and Human Services’ Centers for Medicare and Medicaid Services told states Thursday that the federal government would cease assistance to states to fund nonmedical services geared toward things like nutrition for those enrolled in Medicaid. 

Fox News’ Alec Schemmel contributed to this report. 

This post appeared first on FOX NEWS

previous post
White House quietly floats millionaire tax hike proposal in Congress as GOP leaders signal opposition
next post
Top Hegseth advisor Dan Caldwell placed on administrative leave by Defense Department

You may also like

Ex-Biden advisor calls Jean-Pierre ‘kinda dumb,’ deletes tweet,...

June 6, 2025

More than 230 doctors and health care professionals...

October 16, 2024

Durbin obstruction threat chills Senate as Trump nominees...

June 5, 2025

‘Growing heat’: Sotomayor spars with Alito during LGBTQ...

April 23, 2025

Election 2024: Trump, Harris’ top Hollywood celebrity supporters

November 2, 2024

Harris ripped by Trump campaign after Beyoncé doesn’t...

October 27, 2024

Trump admin cracks down on groups tied to...

March 14, 2025

Trump appoints Alice Marie Johnson ‘pardon czar’ during...

February 21, 2025

Israeli officials confirm Tel Aviv bombing was a...

August 19, 2024

Pentagon ‘fundamentally rejects’ ICC decision to issue arrest...

November 22, 2024

Recent Posts

  • Comey to be arraigned in federal court after being indicted for alleged false statements, obstruction
  • Comey pleads not guilty in court after indictment on alleged false statements, obstruction
  • Houthi rebels test US ceasefire with deadly strike on cargo ship
  • Kushner joins Witkoff for Gaza ceasefire talks as Trump pushes peace plan: ‘Cautiously optimistic’
  • Cuomo rips Mamdani’s freebie ‘fantasy,’ says AOC proved socialism fails after killing NYC Amazon deal

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (936)
    • Investing (3,147)
    • Politics (3,845)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.